Biogen Key Stats
Biogen is one of the oldest independent biotechnology companies in the world. The company specializes in developing therapies for neurological and neurodegenerative diseases. Biogen’s portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, Friedreich’s ataxia, and Alzheimer’s disease.
The company generates approximately 45% of its revenue from MS products and 16% from rare disease treatments. Biogen collaborates with Gilead Sciences and other major pharmaceutical companies on various research initiatives. The company trades on NASDAQ under the ticker symbol BIIB.
Biogen History
The company traces its roots to 1978 when a group of prominent scientists founded Biotechnology Geneva. These researchers recognized the potential of recombinant DNA technology to create new medical treatments. Walter Gilbert served as the initial CEO during the company’s formative years.
Scientists founded Biotechnology Geneva in Switzerland with $6.5 million in initial funding. The team focused on recombinant DNA technology.
Biogen went public on the stock market. The company established research operations across Europe and the United States.
James L. Vincent became CEO and launched a radical restructuring after the company accumulated $100 million in losses.
The FDA approved Avonex for relapsing forms of multiple sclerosis. This became a landmark product for Biogen.
Biogen merged with IDEC Pharmaceuticals in a $6.8 billion deal. The combined company became Biogen Idec.
The company simplified its name from Biogen Idec back to Biogen. Stock reached an all-time high of $475.98 in March.
Biogen launched Spinraza for spinal muscular atrophy. The treatment became the first approved therapy for SMA.
The FDA approved Aduhelm for Alzheimer’s disease through accelerated approval. The decision sparked significant controversy.
Biogen acquired Reata Pharmaceuticals for $7.3 billion. The deal added Skyclarys for Friedreich’s ataxia to the portfolio.
Biogen Co-founders
Five prominent scientists from leading universities established Biogen. Each brought expertise in molecular biology and genetics to the venture. Two founders later received Nobel Prizes for their scientific contributions.
Harvard University professor who served as the first CEO. He received the Nobel Prize in Chemistry in 1980 for DNA sequencing work.
MIT scientist who received the Nobel Prize in Physiology or Medicine in 1993 for discovering split genes. He remains a company director.
University of Zurich professor who developed the company’s first product, interferon alpha. He specialized in molecular biology research.
University of Edinburgh scientist who contributed expertise in genetic engineering and recombinant DNA technology.
University of Heidelberg researcher who brought molecular biology expertise to the founding team.
Biogen Competitors
Biogen competes in the neurology and biotechnology markets against several major pharmaceutical companies. The MS treatment space remains highly competitive with multiple approved therapies. Similar to how Amgen competes across various therapeutic areas, Biogen faces rivalry from both large pharma and specialized biotech firms.
| Company | Headquarters | Key Competing Products |
|---|---|---|
| Novartis | Basel, Switzerland | Gilenya, Kesimpta, Mayzent (MS) |
| Roche/Genentech | Basel, Switzerland | Ocrevus (MS) |
| Sanofi Genzyme | Paris, France | Aubagio, Lemtrada (MS) |
| Bayer | Leverkusen, Germany | Betaseron (MS) |
| Bristol-Myers Squibb | New York, USA | Zeposia (MS) |
| Merck KGaA | Darmstadt, Germany | Mavenclad, Rebif (MS) |
| AbbVie | North Chicago, USA | Neurology pipeline |
| Regeneron | Tarrytown, USA | Neurology therapeutics |
| Eli Lilly | Indianapolis, USA | Donanemab (Alzheimer’s) |
| Eisai | Tokyo, Japan | Leqembi partner (Alzheimer’s) |
Biogen Revenue
Biogen generated $9.7 billion in revenue during 2024. The company experienced a slight decline from 2023 revenue of $9.8 billion. MS products contribute the largest share of total revenue, though generic competition has impacted sales growth.
The company’s rare disease portfolio expanded with the Reata acquisition. Skyclarys and Spinraza now drive growth in the rare disease segment. Similar to Eli Lilly and other major pharma companies, Biogen invests heavily in R&D to maintain its competitive position.
Biogen Marketcap
Biogen maintains a market capitalization of approximately $25.7 billion as of late 2025. The company’s market value peaked at over $100 billion in March 2015 when stock prices reached $475.98 per share. Increased competition and pipeline challenges have reduced the valuation since then.
The company trades on NASDAQ under the ticker BIIB. Biogen ranks among the top biotechnology companies globally by market value. Investment firms like Berkshire Hathaway hold positions in Biogen stock.
Biogen Acquisitions
Biogen has completed 11 acquisitions throughout its history. The company uses acquisitions to expand its therapeutic portfolio and strengthen its pipeline. The largest deal occurred in 2023 when Biogen acquired Reata Pharmaceuticals.
The 2003 merger with IDEC Pharmaceuticals transformed Biogen into the third-largest biotechnology company globally at that time. This deal valued at $6.8 billion brought Rituxan and other oncology products to the portfolio. The combined entity operated as Biogen Idec until 2015 when the name simplified to Biogen.
In July 2023, CEO Christopher Viehbacher led the acquisition of Reata Pharmaceuticals for $7.3 billion. This deal added Skyclarys for Friedreich’s ataxia to Biogen’s rare disease portfolio. The acquisition represented the largest in Biogen’s history by dollar value. Companies like Sanofi and Shire have pursued similar rare disease strategies through acquisitions.
The company acquired HI-Bio in May 2024 for $1.15 billion. This transaction brought felzartamab into the pipeline for treating immune-mediated kidney diseases. Earlier acquisitions include Convergence Pharmaceuticals for up to $675 million in 2015, Nightstar Therapeutics for gene therapy assets in 2019, and Fumapharm AG in 2006 which provided the foundation for Tecfidera.
Biogen also spun off its hemophilia business as Bioverativ in 2017. Baxter International and other healthcare companies have similarly divested non-core segments to focus on primary therapeutic areas. Sanofi subsequently acquired Bioverativ for $11.6 billion in 2018.
FAQs
When was Biogen founded?
Biogen was founded in 1978 in Geneva, Switzerland by five prominent scientists including Nobel Prize winners Walter Gilbert and Phillip Allen Sharp.
Where is Biogen headquarters located?
Biogen is headquartered in Cambridge, Massachusetts. The company plans to move to a new global headquarters at Kendall Square in 2028.
What diseases does Biogen treat?
Biogen develops treatments for multiple sclerosis, spinal muscular atrophy, Friedreich’s ataxia, Alzheimer’s disease, and ALS.
What is Biogen’s annual revenue?
Biogen generated $9.7 billion in revenue during 2024. Multiple sclerosis products contribute approximately 45% of total revenue.
Who are Biogen’s main competitors?
Biogen’s main competitors include Novartis, Roche, Sanofi Genzyme, and Bristol-Myers Squibb in the multiple sclerosis market.